Eschscholzia Californica Whole

Dosage for Eschscholzia Californica Whole is highly individualized and must be determined by an allergist based on the patient's clinical history and skin test reactivity.

Diagnostic Dosing:

• Percutaneous (Prick) Testing: Usually performed with a 1:10 or 1:20 w/v glycerinated extract. A single drop is applied to the skin, which is then pricked.
• Intradermal Testing: If prick tests are negative, a more sensitive intradermal test may be performed using a 1:100 or 1:1000 w/v aqueous solution, injecting approximately 0.02 mL to 0.05 mL.

Immunotherapy Dosing:

• Build-up Phase: Starts with a very low dose (e.g., 0.05 mL of a 1:100,000 w/v dilution) administered once or twice weekly. The dose is gradually increased until the maintenance dose is reached.
• Maintenance Phase: The highest tolerated dose (often 0.5 mL of a 1:100 or 1:10 w/v solution) administered at longer intervals (every 2 to 4 weeks).

Pediatric dosing follows the same principles as adult dosing, though smaller volumes may be used in very young children to minimize discomfort. Safety and efficacy in children under the age of 5 have not been extensively established for all allergenic extracts, and the decision to treat must be made by a specialist.

Renal Impairment

No specific dosage adjustments are required for renal impairment, as the systemic load of the extract is minimal.

Hepatic Impairment

No specific dosage adjustments are required for hepatic impairment.

Elderly Patients

Caution is advised in elderly patients, particularly those with underlying cardiovascular disease, as they may be less able to tolerate the physiological stress of a systemic allergic reaction or the administration of epinephrine if anaphylaxis occurs.

This product is for professional use only. It must be administered in a clinical setting equipped to handle anaphylaxis.

• Storage: Store at 2°C to 8°C (36°F to 46°F). Do not freeze.
• Administration: Subcutaneous injection only for immunotherapy. Never administer intravenously.
• Observation: Patients must remain in the clinic for at least 30 minutes following any injection to monitor for systemic reactions.

In immunotherapy, if a dose is missed, the next dose may need to be reduced depending on how much time has elapsed. If more than 4 weeks have passed since the last dose, the physician may need to restart the build-up phase at a lower concentration to ensure safety.

An overdose of allergenic extract typically results in a severe local reaction or a systemic reaction (anaphylaxis). Symptoms include hives, swelling, wheezing, and hypotension. Treatment involves the immediate administration of epinephrine and supportive care.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.

Most patients receiving Eschscholzia Californica Whole extracts will experience some form of local reaction.

• Local Wheal and Flare: During skin testing, a raised red bump at the site of application is expected in sensitive individuals. This usually resolves within 1-2 hours.
• Injection Site Swelling: In immunotherapy, redness and swelling (up to the size of a half-dollar) are common. This may feel itchy or slightly warm and can last for 24 to 48 hours.

• Large Local Reactions: Swelling that exceeds 5-10 cm in diameter. This may require the use of cold compresses or oral antihistamines.
• Fatigue: Some patients report feeling unusually tired for several hours following an immunotherapy injection.
• Nasal Congestion: A mild increase in hay fever symptoms shortly after administration.

• Systemic Urticaria: Hives appearing on parts of the body away from the injection site.
• Angioedema: Swelling of the deeper layers of the skin, often around the eyes or lips.
• Generalized Pruritus: Intense itching across the entire body.

> Warning: Stop taking Eschscholzia Californica Whole treatments and call your doctor immediately if you experience any of these symptoms of anaphylaxis:

• Respiratory Distress: Difficulty breathing, wheezing, or a feeling of tightness in the chest.
• Laryngeal Edema: A 'lump in the throat,' hoarseness, or difficulty swallowing.
• Hypotension: Dizziness, fainting, or a rapid, weak pulse indicating a drop in blood pressure.
• Cyanosis: A bluish tint to the lips or fingernails.
• Uterine Contractions: In pregnant women, systemic reactions can trigger premature labor.

There are no known long-term 'toxic' side effects associated with the proper use of allergenic extracts. The primary risk of long-term immunotherapy is the cumulative risk of having a systemic reaction over the course of the 3-5 year treatment period.

While Eschscholzia Californica Whole may not have an individual black box warning for every manufacturer, the class of allergenic extracts carries a general warning regarding the risk of severe non-fatal and fatal systemic reactions. These extracts should only be used by physicians experienced in the diagnosis and treatment of allergic diseases and must be administered where emergency equipment is available.

Report any unusual symptoms to your healthcare provider.

Eschscholzia Californica Whole allergenic extract is intended for use only by clinicians trained in allergy management. Because it contains potent allergens, it can cause life-threatening allergic reactions even in small doses.

No specific FDA black box warning exists for the Eschscholzia Californica species specifically, but all allergenic extracts are governed by the general warning that they can cause anaphylaxis. Anaphylaxis is a medical emergency that requires immediate treatment with epinephrine. Patients with unstable asthma are at a higher risk for fatal reactions.

• Allergic Reactions / Anaphylaxis Risk: The most significant risk is a systemic allergic reaction. This is more likely during the build-up phase of immunotherapy or if the patient is highly sensitive.
• Asthma Exacerbation: Patients with poorly controlled asthma should not receive immunotherapy or skin testing until their asthma is stabilized, as they are at a significantly higher risk for severe respiratory compromise during a reaction.
• Cardiovascular Disease: Patients with pre-existing heart conditions may be at higher risk if they require epinephrine, which increases heart rate and oxygen demand.

• Wait Time: Patients must be monitored for at least 30 minutes post-injection.
• Peak Flow: For asthmatic patients, a peak flow meter may be used before administration to ensure lung function is at its baseline.
• Skin Assessment: The site of injection or testing must be inspected for large local reactions before the patient leaves the clinic.

While the extract itself does not cause sedation, a systemic reaction or the administration of antihistamines/epinephrine to treat a reaction can impair the ability to drive. Patients should ensure they feel completely normal before operating a vehicle.

Alcohol should be avoided on the day of an immunotherapy injection, as it can increase blood flow to the skin and potentially accelerate the absorption of the allergen, increasing the risk of a systemic reaction.

Immunotherapy is typically discontinued if the patient experiences a life-threatening systemic reaction or if there is no clinical improvement after 12-24 months of maintenance therapy.

> Important: Discuss all your medical conditions with your healthcare provider before starting Eschscholzia Californica Whole.

• Beta-Blockers (e.g., Propranolol, Atenolol): These medications are generally contraindicated in patients receiving allergenic extracts. Beta-blockers can make an allergic reaction more severe and, more importantly, they can make the patient resistant to the effects of epinephrine, which is the primary treatment for anaphylaxis.

• ACE Inhibitors (e.g., Lisinopril): These may increase the risk of systemic reactions or worsen the severity of hypotension during anaphylaxis.
• Tricyclic Antidepressants (TCAs) and MAOIs: These can potentiate the effect of epinephrine, leading to dangerous spikes in blood pressure if a reaction occurs and epinephrine is administered.

• Antihistamines (e.g., Cetirizine, Loratadine): These must be stopped several days before diagnostic skin testing as they will suppress the wheal and flare reaction, leading to a false-negative result.
• H2 Blockers (e.g., Famotidine): May also interfere with skin test results, though to a lesser extent than H1 blockers.

There are no direct food interactions with the extract itself. However, patients should avoid heavy meals and vigorous exercise for 2 hours before and after an injection, as these can increase systemic absorption rates.

• St. John's Wort: May theoretically affect the metabolism of medications used to treat allergic reactions.
• Herbal Sedatives: Since the California Poppy is also used as a herbal supplement, patients taking oral Eschscholzia californica supplements should inform their doctor, as this may complicate the assessment of their allergy profile.

Eschscholzia Californica Whole extract does not typically interfere with standard blood chemistry or hematology labs. However, it will directly affect the results of Skin Prick Tests and can influence the results of In Vitro IgE testing (like RAST or ImmunoCAP).

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

• Severe, Uncontrolled Asthma: Patients with a Forced Expiratory Volume in 1 second (FEV1) consistently below 70% of predicted values should not start immunotherapy due to the risk of fatal bronchospasm.
• Recent Myocardial Infarction (Heart Attack): The risk of a systemic reaction and the subsequent need for epinephrine pose an unacceptable risk to a recovering heart.
• Hypersensitivity to Extract Components: Any known previous anaphylactic reaction to the specific components of the Eschscholzia Californica extract (excluding the expected allergic response).

• Beta-Blocker Therapy: While often considered absolute, in some cases, a risk-benefit analysis may allow for treatment if the beta-blocker is essential and no alternative exists.
• Autoimmune Diseases: Patients with active systemic autoimmune disorders may have unpredictable immune responses to immunotherapy.
• Pregnancy: While maintenance immunotherapy can often be continued during pregnancy, starting a new 'build-up' phase is generally avoided due to the risk of anaphylaxis-induced fetal hypoxia.

Patients allergic to California Poppy may show cross-reactivity with other members of the Papaveraceae family (the poppy family). Caution should be exercised if the patient has had severe reactions to other poppies or related botanical extracts.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Eschscholzia Californica Whole.

Eschscholzia Californica Whole is classified as FDA Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. The primary risk during pregnancy is maternal anaphylaxis, which can lead to uterine contractions, placental abruption, and fetal hypoxia. Immunotherapy should not be started during pregnancy, but maintenance doses may be continued if the benefit outweighs the risk.

It is not known whether the allergenic components of the extract are excreted in human milk. Because most allergens are large proteins that are digested if ingested by the infant, the risk is generally considered low. However, caution should be exercised when administering injections to a nursing woman.

Skin testing is safe in children of almost any age, though it is rarely performed on infants under 6 months. Immunotherapy is generally reserved for children 5 years of age and older who can cooperate with the procedure and communicate symptoms of a systemic reaction.

Clinical studies of allergenic extracts did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. The main concern in the elderly is the presence of comorbid conditions (heart disease, COPD) that would make them less resilient in the event of a systemic reaction.

No specific studies have been conducted in patients with renal impairment. However, given the nature of the product (proteins), no significant accumulation is expected.

No dosage adjustments are suggested for patients with hepatic impairment, as the liver does not play a primary role in the clearance of injected allergens.

> Important: Special populations require individualized medical assessment.

Eschscholzia Californica Whole extract contains a complex mixture of proteins, glycoproteins, and polysaccharides. The primary allergens are the pollen proteins. In sensitized individuals, these proteins act as antigens that bind to bivalent IgE antibodies on the surface of mast cells and basophils. This binding triggers a signal transduction cascade involving tyrosine kinases, leading to the influx of calcium ions and the exocytosis of pre-formed mediators like histamine.

The pharmacodynamic effect of a diagnostic dose is seen within 15-20 minutes as a wheal (swelling) and flare (redness). The duration of this effect is typically 1-2 hours. In immunotherapy, the pharmacodynamic effect is a long-term modulation of the immune system, characterized by a decrease in allergen-specific IgE and an increase in allergen-specific IgG4.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Local/SC administration) |

| Protein Binding | High (to IgE/IgG antibodies) |

| Half-life | Minutes to hours (proteolysis) |

| Tmax | 15-20 minutes (for skin reaction) |

| Metabolism | Proteolytic degradation |

| Excretion | Renal (as peptide fragments) |

Eschscholzia Californica Whole extract is a biological product derived from the entire plant or specific parts (pollen). It is not a single chemical formula. The extract contains various alkaloids (such as californidine and protopine), though the allergenic proteins are the primary active constituents in this clinical context.

It is classified as a Non-Standardized Plant Allergenic Extract. It belongs to the broader therapeutic category of Allergenics, which includes diagnostic antigens and immunotherapy vaccines.